A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01541618|
Recruitment Status : Unknown
Verified February 2012 by MSDx, Inc..
Recruitment status was: Recruiting
First Posted : March 1, 2012
Last Update Posted : March 1, 2012
|Condition or disease||Intervention/treatment|
|Relapsing Remitting Multiple Sclerosis||Other: MSDX Complex-1 Biomarker test|
|Study Type :||Observational|
|Estimated Enrollment :||15 participants|
|Official Title:||A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis|
|Study Start Date :||January 2012|
|Estimated Primary Completion Date :||July 2012|
|Estimated Study Completion Date :||July 2012|
Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
Other: MSDX Complex-1 Biomarker test
MSDX Complex-1 Biomarker test
Other Name: Biomarker Test
- Change in MSDX Complex-1 between baseline and 6-month visit [ Time Frame: 6 months ]This outcome measure will evaluate a difference in the level of MSDX Complex-1 form the baseline visit to the 6-month visit. MSDX Complex-1 is a biomarker for MS disease activity and its change should correspond with a change in the disease activity in MS.
- Gadolinium MRI and MSDX Complex-1 level [ Time Frame: 6 months ]This outcome will evaluate whether a change seen in a Gadolinium MRI (a diagnostic test for MS) matches with a change in the MSDX Complex-1 level in a patient with MS.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01541618
|United States, Arizona|
|Northwest NeuroSpecialists, PLLC||Recruiting|
|Tucson, Arizona, United States, 85741|
|Contact: Jeanette Wendt, MD 520-742-7890|
|Principal Investigator: Jeanette Wendt, MD|
|Principal Investigator:||Jeannette Wendt, MD||Northwest NeuroSpecialists, PLLC|